Nevertheless, it will be of interest to follow the response to new drugs, including small molecule kinase inhibitors, currently developed to target CSF-1R in cancer in which the receptor is often over-expressed, either on tumor cells or in the microenvironment [88]. The gene discussed is CSF1R; the disease is neoplasm.